Plant-Based
Biotechnology
for Accessible
Vaccine Innovation
GreenHelix Biotech Ltd harnesses the power of molecular plant farming to engineer cost-effective, scalable, and cold-chain-free vaccines — making immunization accessible to every community on earth.
Three Pillars of Biotechnology
Our integrated platform operates across medical, agricultural, and environmental biotechnology — a convergent approach to planetary health.
Medical Biotechnology
Plant-derived vaccine antigens engineered for efficacy, stability, and global distribution without cold-chain dependency.
Core FocusAgricultural Biotechnology
Precision genetic engineering of plant systems as biofactories for pharmaceutical-grade protein expression.
Platform TechEnvironmental Biotech
Sustainable, low-carbon bioprocessing models aligned with global climate and ecological responsibility goals.
ESG AlignedDevelopment Stage
Pre-clinical research phase with active in-silico and laboratory validation of HBsAg antigen expression constructs.
Pre-ClinicalThe Team Behind the Science
Ethics & Research Integrity
Our commitment to ethical scientific conduct
GreenHelix adheres to the highest international standards of research ethics, biosafety, and scientific transparency. All research activities are conducted in compliance with relevant institutional, national, and international regulatory guidelines. We are committed to open science, responsible disclosure, and community engagement in all research involving public health applications.
The Problem We Solve
Vaccine inaccessibility is a systemic failure — one that plant biotechnology is uniquely positioned to resolve.
Cold-Chain Dependency
Conventional vaccines require continuous 2–8°C refrigeration, making rural distribution nearly impossible in Africa and South Asia.
High Production Costs
Traditional bioreactor-based manufacturing costs $5–$40 per dose, pricing out low-income health systems.
Manufacturing Gaps
Over 99% of vaccines consumed in Africa are imported, creating dangerous supply chain vulnerabilities.
Slow Response Capacity
Conventional platforms require 6–18 months to scale for outbreak response — too slow for pandemic control.
Thermostable Plant Antigens
Plant-expressed proteins offer natural stability, reducing or eliminating cold-chain infrastructure requirements.
Dramatically Lower Costs
Molecular farming leverages agricultural infrastructure, cutting production costs by an estimated 60–80% versus conventional methods.
Local Manufacturing Model
Our platform is designed to operate in African contexts — scalable in greenhouses and low-resource agricultural settings.
Rapid Antigen Redesign
Genetic engineering enables fast adaptation of expression constructs in response to emerging pathogen variants.
Our Science, Simplified
Molecular Farming
Using Nicotiana benthamiana and other high-expression plant hosts as biofactories for scalable recombinant protein production.
Genetic Engineering
Agrobacterium-mediated transient expression and stable transformation strategies for optimized antigen yield and folding.
Antigen Expression
Hepatitis B surface antigen (HBsAg) as lead model — a clinically validated target with global epidemiological relevance.
HBsAg Development Roadmap
A structured four-phase pathway from construct design to preclinical validation.
A Market Ready for Disruption
The global plant-based biopharmaceutical market is projected to exceed $36 billion by 2030. GreenHelix is building the infrastructure to capture African market leadership.